Innoviva (INVA) Net Income Growth (3y) (2013 - 2026)
Innoviva (INVA) Net Income Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - | 9.16% |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.60 Bn | 466.80 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 121.71 Bn | 114.46 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 69.83 Bn | 61.07 Bn | 3.31 Bn | -3.84% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | 79.26% |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn | 47.10% |
| 10 | Innoviva | 1.59 Bn | 986.53 Mn | 75.83 Mn | 74.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 74.96% |
| Dec 31, 2025 | -2.43% |
| Sep 30, 2025 | -28.15% |
| Jun 30, 2025 | 43.85% |
| Mar 31, 2025 | -47.83% |
| Dec 31, 2024 | 29.78% |
| Sep 30, 2024 | -78.77% |
| Jun 30, 2024 | -32.25% |
| Mar 31, 2024 | -30.70% |
| Dec 31, 2023 | -48.85% |
| Sep 30, 2023 | 41.65% |
| Jun 30, 2023 | -76.32% |
| Mar 31, 2023 | -23.87% |
| Dec 31, 2022 | -31.52% |
| Sep 30, 2022 | 83.05% |
| Jun 30, 2022 | -22.56% |
| Mar 31, 2022 | -1.84% |
| Dec 31, 2021 | -29.40% |
| Sep 30, 2021 | 86.07% |
| Jun 30, 2021 | 25.10% |